Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 2020

View Archived Issues

Integrated herpesvirus 6 is pre-eclampsia risk factor

Sorrento Therapeutics and Mount Sinai partner on antibody cocktail for COVID-19

Tukysa approved in Switzerland for metastatic HER2-positive breast cancer

GALNT14 GG genotype as prognostic biomarker in PDA

Decreased SLC39A1 expression is associated with poor prognosis in HCC

AQX-435 shows promising activity in models of B-cell malignancies

ALS-8112, a parent nucleoside of lumicitabine, inhibits Nipah virus in vitro

Phase III data presented on fexuprazan in patients with erosive esophagitis

miR-802 overexpression links obesity with impaired insulin transcription and secretion

NTRK1 inhibitors discovered at Medshine Discovery

Step Pharma identifies new CTP synthase 1 inhibitors

Myelopro Diagnostics & Research presents new compounds binding to calreticulin

Enabling P-TEFb-dependent transcription of Myc in heart restores cardiomyocyte proliferation

New anthelmintic compounds patented by Bayer

C4X Discovery Holdings presents NFE2-related factor 2 activators

New biomarker identified for the aging brain

Blade Therapeutics begins phase II study of BLD-2660 in hospitalized patients with COVID-19

Genocea eyes IND filing for neoantigen cell therapy GEN-011

Arrowhead opens enrollment in phase Ib study of ARO-HIF2 in advanced clear cell renal cell carcinoma

Veru cleared by FDA to begin phase II study of VERU-111 for COVID-19

TransThera studies TT-00920 for heart failure in first-in-human study

New compounds target SARS-CoV-2 main protease Mpro

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...